Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA

Neurochemistry International

Volumn 63, Issue 8, 2013, Pages 790-804

  Lorenc Koci, Elzbieta ^a   Czarnecka, Anna ^a   Lenda, Tomasz ^a   Kamińska, Kinga ^a   Konieczny, Jolanta ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

6 OHDA animal model of Parkinson's disease; Dopamine and serotonin metabolism; L DOPA; Molsidomine; Nitric oxide; Rotational behavior

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; BENSERAZIDE; DOPAMINE; HOMOVANILLIC ACID; LEVODOPA; MOLSIDOMINE; MONOAMINE; NITRIC OXIDE; OXIDOPAMINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CATABOLISM; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DRUG DOSE COMPARISON; LONG TERM CARE; LOW DRUG DOSE; MALE; MONOAMINE METABOLISM; MONOTHERAPY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; TISSUE LEVEL;

ANIMALIA; RATTUS;

3,4-DIHYDROXYPHENYLACETIC ACID; 5-HIAA; 5-HT; 5-HYDROXYINDOLEACETIC ACID; 6-HYDROXYDOPAMINE HYDROCHLORIDE; 6-OHDA; 6-OHDA ANIMAL MODEL OF PARKINSON'S DISEASE; ANALYSIS OF VARIANCE; ANOVA; DA; DOPAC; DOPAMINE; DOPAMINE AND SEROTONIN METABOLISM; HIGH-PRESSURE LIQUID CHROMATOGRAPHY; HOMOVANILLIC ACID; HPLC; HVA; L-DOPA; MAO; MOLSIDOMINE; MONOAMINE OXIDASE; NITRIC OXIDE; PARKINSON'S DISEASE; PD; ROTATIONAL BEHAVIOR; SEROTONIN; SNC; SNR; STR; STRIATUM; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATE;

ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; LEVODOPA; MALE; MOLSIDOMINE; NITRIC OXIDE DONORS; OXIDOPAMINE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA;

EID: 84887153216     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2013.09.021     Document Type: Article

References (101)

1. T. Abekawa, T. Ohmori, and T. Koyama Effect of NO synthase inhibition on behavioral changes induced by a single administration of methamphetamine Brain Res. 666 1994 147 150
2. K.D. Alex, and E.A. Pehek Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission Pharmacol. Ther. 113 2007 296 320
3. R. Arai, N. Karasawa, M. Geffard, T. Nagatsu, and I. Nagatsu Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase Brain Res. 667 1994 295 299
4. F. Bergquist, H.N. Shahabi, and H. Nissbrandt Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod Brain Res. 973 2003 81 91
5. M.D. Black, E.K. Matthews, and P.P. Humphrey The effects of a photosensitive nitric oxide donor on basal and electrically-stimulated dopamine efflux from the rat striatum in vitro Neuropharmacology 33 1994 1357 1365
6. M.L. Block, L. Zecca, and J.S. Hong Microglia-mediated neurotoxicity: uncovering the molecular mechanisms Nat. Rev. Neurosci. 8 2007 57 69
7. R. Böckelmann, G. Wolf, G. Ransmayr, and P. Riederer NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen J. Neural. Transm. Park Dis. Dement Sect. 7 1994 115 121
8. R.H. Böger, S.M. Bode-Böger, U. Gerecke, and J.C. Frölich Long-term administration of L-arginine, L-NAME, and the exogenous NO donor molsidomine modulates urinary nitrate and cGMP excretion in rats Cardiovasc. Res. 28 1994 494 499
9. R.L. Büyükuysal Effect of nitric oxide donors on endogenous dopamine release from rat striatal slices. II: The role of voltage-dependent sodium channels, calcium channel activation, reverse transport mechanism, guanylate cyclase and endogenous glutamate Fundam. Clin. Pharmacol. 11 1997 528 536
10. V. Calabrese, C. Mancuso, M. Calvani, E. Rizzarelli, D.A. Butterfield, and A.M. Stella Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity Nat. Rev. Neurosci. 8 2007 766 775
11. A. Calignano, P. Persico, F. Mancuso, and L. Sorrentino Endogenous nitric oxide modulates morphine-induced changes in locomotion and food intake in mice Eur. J. Pharmacol. 231 1993 415 419
12. R.J. Carey Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance Brain Res. 568 1991 205 214
13. M. Cavas, and J.F. Navarro Coadministration of L-NOARG and tiapride: effects on catalepsy in male mice Prog. Neuropsychopharmacol. Biol. Psychiatry 26 2002 69 73
14. Y.B. Choi, L. Tenneti, D.A. Le, J. Ortiz, G. Bai, H.S. Chen, and S.A. Lipton Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation Nat. Neurosci. 3 2000 15 21
15. A.D. Crocker The regulation of motor control: an evaluation of the role of dopamine receptors in the substantia nigra Rev. Neurosci. 8 1997 55 76
16. E.A. Del Bel, F.S. Guimarães, M. Bermúdez-Echeverry, M.Z. Gomes, A. Schiaveto-de-souza, F.E. Padovan-Neto, V. Tumas, A.P. Barion-Cavalcanti, M. Lazzarini, L.P. Nucci-da-Silva, and D. de Paula-Souza Role of nitric oxide on motor behavior Cell. Mol. Neurobiol. 25 2005 371 392
17. E.A. Del Bel, C.A. da-Silva, and F.S. Guimaraes Catalepsy induced by nitric oxide synthase inhibitors Gen. Pharmacol. 30 1998 245 248
18. S.I. Deutsch, R.B. Rosse, S.M. Paul, V. Tomasino, L. Koetzner, C.B. Morn, and J. Mastropaolo 7-Nitroindazole and methylene blue, inhibitors of neuronal nitric oxide synthase and NO-stimulated guanylate cyclase, block MK-801-elicited behaviors in mice Neuropsychopharmacology 15 1996 37 43
19. J. de Vente, M. Markerink-van Ittersum, J. van Abeelen, P.C. Emson, H. Axer, and H.W. Steinbusch NO-mediated cGMP synthesis in cholinergic neurons in the rat forebrain: effects of lesioning dopaminergic or serotonergic pathways on nNOS and cGMP synthesis Eur. J. Neurosci. 12 2000 507 519
20. V. Di Matteo, M. Pierucci, A. Benigno, G. Crescimanno, E. Esposito, and G. Di Giovanni Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: a neurochemical study Ann. N. Y. Acad. Sci. 1155 2009 309 315
21. E. Dzoljic, R. De Vries, and M.R. Dzoljic New and potent inhibitors of nitric oxide synthase reduce motor activity in mice Behav. Brain Res. 87 1997 209 212
22. D.J. Eve, A.P. Nisbet, A.E. Kingsbury, E.L. Hewson, S.E. Daniel, A.J. Lees, C.D. Marsden, and O.J. Foster Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease Brain Res. Mol. Brain Res. 63 1998 62 71
23. L. Frau, M. Morelli, and N. Simola Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons Exp. Neurol. 247 2013 663 672
24. M. Giorgi, V. D'Angelo, Z. Esposito, V. Nuccetelli, R. Sorge, A. Martorana, A. Stefani, G. Bernardi, and G. Sancesario Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms Eur. J. Neurosci. 28 2008 941 950
25. A.A. Grace, and B.S. Bunney Paradoxical GABA excitation of nigral dopaminergic cells: indirect mediation through reticulata inhibitory neurons Eur. J. Pharmacol. 59 1979 211 218
26. A.A. Grace, and B.S. Bunney Opposing effects of striatonigral feedback pathways on midbrain dopamine cell activity Brain Res. 333 1985 271 284
27. F.X. Guix, I. Uribesalgo, M. Coma, and F.J. Muñoz The physiology and pathophysiology of nitric oxide in the brain Prog. Neurobiol. 76 2005 126 152
28. R. Guevara-Guzman, P.C. Emson, and K.M. Kendrick Modulation of in vivo striatal transmitter release by nitric oxide and cyclic GMP J. Neurochem. 62 1994 807 810
29. K.L. Haik, D.A. Shear, C. Hargrove, J. Patton, M. Mazei-Robison, M.I. Sandstrom, and G.L. Dunbar 7-nitroindazole attenuates 6-hydroxydopamine-induced spatial learning deficits and dopamine neuron loss in a presymptomatic animal model of Parkinson's disease Exp. Clin. Psychopharmacol. 16 2008 178 189
30. B. Henry, A.R. Crossman, and J.M. Brotchie Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease Exp. Neurol. 151 1998 334 342
31. E.C. Hirsch, S. Hunot, P. Damier, and B. Faucheux Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann. Neurol. 44 1998 S115 S120
32. K.E. Hoque, R.P. Indorkar, S. Sammut, and A.R. West Impact of dopamine-glutamate interactions on striatal neuronal nitric oxide synthase activity Psychopharmacology 207 2010 571 581
33. J.L. Hudson, C.G. van Horne, I. Strömberg, S. Brock, J. Clayton, J. Masserano, B.J. Hoffer, and G.A. Gerhardt Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats Brain Res. 626 1993 167 174
34. M.M. Iravani, J. Millar, and Z.L. Kruk Differential release of dopamine by nitric oxide in subregions of rat caudate putamen slices J. Neurochem. 71 1998 1969 1977
35. M.M. Iravani, K. Kashefi, P. Mander, S. Rose, and P. Jenner Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration Neuroscience 110 2002 49 58
36. N. Jonkers, S. Sarre, G. Ebinger, and Y. Michotte MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats Brain Res. 926 2002 149 155
37. P.H. Kelly, and S.D. Iversen Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats Eur. J. Pharmacol. 40 1976 45 56
38. W.K. Kim, Y.B. Choi, P.V. Rayudu, P. Das, W. Asaad, D.R. Arnelle, J.S. Stamler, and S.A. Lipton Attenuation of NMDA receptor activity and neurotoxicity by nitroxyl anion, NO- Neuron 24 1999 461 469
39. J.P. Kiss Role of nitric oxide in the regulation of monoaminergic neurotransmission Brain Res. Bull. 52 2000 459 466
40. J.P. Kiss, and E.S. Vizi Nitric oxide: a novel link between synaptic and nonsynaptic transmission Trends Neurosci. 24 2001 211 215
41. J.P. Kiss, G. Zsilla, and E.S. Vizi Inhibitory effect of nitric oxide on dopamine transporters: interneuronal communication without receptors Neurochem. Int. 45 2004 485 489
42. P. Krza̧ścik, and W. Kostowski Nitric oxide donors antagonize N-nitro-L-arginine and haloperidol catalepsy: potential implication for the treatment of Parkinsonism? Pol. J. Pharmacol. 49 1997 263 266
43. M.A. Kuiper, J.J. Visser, P.L. Bergmans, P. Scheltens, and E.C. Wolters Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients J. Neurol. Sci. 121 1994 46 49
44. Y. Kurauchi, A. Hisatsune, Y. Isohama, and H. Katsuki Nitric oxide-cyclic GMP signaling pathway limits inflammatory degeneration of midbrain dopaminergic neurons: cell type-specific regulation of heme oxygenase-1 expression Neuroscience 158 2009 856 866
45. E.L. Lane, S.C. Cheetham, and P. Jenner Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Exp. Neurol. 197 2006 284 290
46. L.P. Liang, and S. Kaufman The regulation of dopamine release from striatum slices by tetrahydrobiopterin and L-arginine-derived nitric oxide Brain Res. 800 1998 181 186
47. H.S. Lindgren, D. Rylander, K.E. Ohlin, M. Lundblad, and M.A. Cenci The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration Behav. Brain Res. 177 2007 150 159
48. S.A. Lipton, Y.B. Choi, Z.H. Pan, S.Z. Lei, H.S. Chen, N.J. Sucher, J. Loscalzo, D.J. Singel, and J.S. Stamler A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds Nature 364 1993 626 632
49. 3H]dopamine release from striatal slices J. Neurosci. Res. 35 1993 192 198
50. M. Maccario, S.E. Oleandri, M. Procopio, S. Grottoli, E. Avogadri, F. Camanni, and E. Ghigo Comparison among the effects of arginine, a nitric oxide precursor, isosorbide dinitrate and molsidomine, two nitric oxide donors, on hormonal secretions and blood pressure in man J. Endocrinol. Invest. 20 1997 488 492
51. P.L. McGeer, C. Schwab, A. Parent, and D. Doudet Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration Ann. Neurol. 54 2003 599 604
52. F. Mancuso, A. Calignano, and L. Sorrentino Endogenous nitric oxide modulates behavioural effects elicited by substance P in rat Eur. J. Pharmacol. 271 1994 329 333
53. O. Manzoni, and J. Bockaert Nitric oxide synthase activity endogenously modulates NMDA receptors J. Neurochem. 61 1993 368 670
54. O. Manzoni, L. Prezeau, P. Marin, S. Deshager, J. Bockaert, and L. Fagni Nitric oxide-induced blockade of NMDA receptors Neuron 8 1992 653 662
55. R.A. Marras, A.P. Martins, E.A. Del Bel, and F.S. Guimaraes L-NOARG, an inhibitor of nitric oxide synthase, induces catalepsy in mice Neuroreport 7 1995 158 160
56. W.G. Mayhan Nitric oxide donor-induced increase in permeability of the blood-brain barrier Brain Res. 866 2000 101 108
57. R.C. Meyer, E.L. Spangler, N. Patel, E.D. London, and D.K. Ingram Impaired learning in rats in a 14-unit T-maze by 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, is attenuated by the nitric oxide donor, molsidomine Eur. J. Pharmacol. 341 1998 17 22
58. K.J. Min, M.S. Yang, S.U. Kim, I. Jou, and E.H. Joe Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation J. Neurosci. 26 2006 1880 1887
59. S. Navailles, B. Bioulac, C. Gross, and P. De Deurwaerdère Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease Neurobiol. Dis. 38 2010 136 143
60. S. Navailles, B. Bioulac, C. Gross, and P. De Deurwaerdère Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease Neurobiol. Dis. 41 2011 585 590
61. M. Ohno, and S. Watanabe Nitric oxide synthase inhibitors block behavioral sensitization to methamphetamine in mice Eur. J. Pharmacol. 275 1995 39 44
62. F.E. Padovan-Neto, M.B. Echeverry, V. Tumas, and E.A. Del-Bel Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease Neuroscience 159 2009 927 935
63. D.J. Park, and A.R. West Regulation of striatal nitric oxide synthesis by local dopamine and glutamate interactions J. Neurochem. 111 2009 1457 1465
64. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 1986 Academic Press San Diego
65. B. Picconi, V. Bagetta, V. Ghiglieri, V. Di Paillè, M. Filippo, V. Pendolino, A. Tozzi, C. Giampà, F.R. Fusco, C. Sgobio, and P. Calabresi Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia Brain 134 2011 375 387
66. N. Pitsikas, A.E. Rigamonti, S.G. Cella, V. Locatelli, M. Sala, and E.E. Muller Effects of molsidomine on scopolamine-induced amnesia and hypermotility in the rat Eur. J. Pharmacol. 426 2001 193 200
67. N. Pitsikas, A.E. Rigamonti, S.G. Cella, and E.E. Muller Effects of the nitric oxide donor molsidomine on different memory components as assessed in the object-recognition task in the rat Psychopharmacology 162 2002 239 245
68. N. Pitsikas, A.E. Rigamonti, S.G. Cella, and E.E. Muller The GABAB receptor and recognition memory: possible modulation of its behavioral effects by the nitrergic system Neuroscience 118 2003 1121 1127
69. N. Pitsikas, A.E. Rigamonti, S.G. Cella, N. Sakellaridis, and E.E. Muller The nitric oxide donor molsidomine antagonizes age-related memory deficits in the rat Neurobiol. Aging 26 2005 259 264
70. N. Pitsikas, S. Zisopoulou, and N. Sakellaridis Nitric oxide donor molsidomine attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801 J. Neurosci. Res. 84 2005 299 305
71. E. Przegaliński, and M. Filip Nitric oxide (NO) pathway and locomotor hyperactivity towards dopaminomimetics in rats Pol. J. Pharmacol. 49 1997 291 298
72. C.M. Pudiak, and M.A. Bozarth L-NAME and MK-801 attenuate sensitization to the locomotor-stimulating effect of cocaine Life Sci. 53 1993 1517 1524
73. J. Reden Molsidomine Blood Vessels 27 1990 282 294
74. G.S. Robertson, and H.A. Robertson Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms J. Neurosci. 9 1989 3326 3331
75. H.A. Robertson, M.R. Peterson, K. Murphy, and G.S. Robertson D1-dopamine receptor agonists selectively activate striatal c-fos independent of rotational behaviour Brain Res. 503 1989 346 349
76. B. Rosenkranz, B.R. Winkelmann, and M.J. Parnham Clinical pharmacokinetics of molsidomine Clin. Pharmacokinet. 30 1996 372 384
77. S. Sammut, A. Dec, D. Mitchell, J. Linardakis, M. Ortiguela, and A.R. West Phasic dopaminergic transmission increases NO efflux in the rat dorsal striatum via a neuronal NOS and a dopamine D(1/5) receptor-dependent mechanism Neuropsychopharmacology 31 2006 493 505
78. S. Sammut, K.E. Bray, and A.R. West Dopamine D2 receptor-dependent modulation of striatal NO synthase activity Psychopharmacology 191 2007 793 803
79. G. Sancesario, M. Giorgi, V. D'Angelo, A. Modica, A. Martorana, M. Morello, C.P. Bengtson, and G. Bernardi Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation Eur. J. Neurosci. 20 2004 989 1000
80. C. Sandi, C. Venero, and C. Guaza Decreased spontaneous motor activity and startle response in nitric oxide synthase inhibitor-treated rats Eur. J. Pharmacol. 277 1995 89 97
81. J.B. Schulz, R.T. Matthews, M.M. Muqit, S.E. Browne, and M.F. Beal Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice J. Neurochem. 64 1995 936 939
82. H. Shibata, H. Katsuki, M. Nishiwaki, T. Kume, S. Kaneko, and A. Akaike Lipopolysaccharide-induced dopaminergic cell death in rat midbrain slice cultures: role of inducible nitric oxide synthase and protection by indomethacin J. Neurochem. 86 2003 1201 1212
83. S. Singh, T. Das, A. Ravindran, R.K. Chaturvedi, Y. Shukla, A.K. Agarwal, and M. Dikshit Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease Redox Rep. 10 2005 103 109
84. M.S. Starr, and B.S. Starr Do NMDA receptor-mediated changes in motor behaviour involve nitric oxide? Eur. J. Pharmacol. 272 1995 211 217
85. J. Stewart, S.E. Deschamps, and S. Amir Inhibition of nitric oxide synthase does not block the development of sensitization to the behavioral activating effects of amphetamine Brain Res. 641 1994 141 144
86. 3H] dopamine from rat striatum in vitro J. Neurochem. 66 1996 131 137
87. H. Tanaka, K. Kannari, T. Maeda, M. Tomiyama, T. Suda, and M. Matsunaga Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats Neuroreport 10 1999 631 634
88. W. Timmerman, and E.D. Abercrombie Amphetamine-induced release of dendritic dopamine in substantia nigra pars reticulata: D1-mediated behavioral and electrophysiological effects Synapse 23 1996 280 291
89. J.T. Trevitt, B.B. Carlson, K. Nowend, and J.D. Salamone Substantia nigra pars reticulata is a highly potent site of action for the behavioral effects of the D1 antagonist SCH 23390 in the rat Psychopharmacology 156 2001 32 41
90. T. Trevitt, B. Carlson, M. Correa, A. Keene, M. Morales, and J.D. Salamone Interactions between dopamine D1 receptors and gamma-aminobutyric acid mechanisms in substantia nigra pars reticulata of the rat: neurochemical and behavioral studies Psychopharmacology 159 2002 229 237
91. U. Ungerstedt Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system Acta Physiol. Scand. Suppl. 367 1971 69 93
92. Y. Watanabe, H. Kato, and T. Araki Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease Metab. Brain Dis. 23 2008 51 69
93. A.R. West, and M.P. Galloway Intrastriatal infusion of ()-S-nitroso-N-acetylpenicillamine releases vesicular dopamine via an ionotropic glutamate receptor-mediated mechanism: an in vivo microdialysis study in chloral hydrate-anesthetized rats J. Neurochem. 66 1996 1971 1980
94. A.R. West, and M.P. Galloway Endogenous nitric oxide facilitates striatal dopamine and glutamate efflux in vivo: role of ionotropic glutamate receptor-dependent mechanisms Neuropharmacology 36 1997 1571 1581
95. A.R. West, and M.P. Galloway Nitric oxide and potassium chloride-facilitated striatal dopamine efflux in vivo: role of calcium-dependent release mechanisms Neurochem. Int. 33 1998 493 501
96. A.R. West, M.P. Galloway, and A.A. Grace Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms Synapse 44 2002 227 245
97. A.R. West, and A.A. Grace Striatal nitric oxide signaling regulates the neuronal activity of midbrain dopamine neurons in vivo J. Neurophysiol. 83 2000 1796 1808
98. A.R. West, and K.Y. Tseng Nitric oxide-soluble guanylyl cyclase-cyclic GMP signaling in the striatum: new targets for the treatment of Parkinson's disease? Front. Syst. Neurosci. 5 2011 1 9
99. H. Yamada, Y. Aimi, I. Nagatsu, K. Taki, M. Kudo, and R. Arai Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats Neurosci. Res. 59 2007 1 7
100. J.E. Yuste, M.B. Echeverry, F. Ros-Bernal, A. Gomez, C.M. Ros, C.M. Campuzano, E. Fernandez-Villalba, and M.T. Herrero 7-Nitroindazole down-regulates dopamine/DARPP-32 signaling in neostriatal neurons in a rat model of Parkinson's disease Neuropharmacology 63 2012 1258 1267
101. X.Z. Zhu, and L.G. Luo Effect of nitroprusside (nitric oxide) on endogenous dopamine release from rat striatal slices J. Neurochem. 59 1992 932 935